Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.67 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.57 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.57 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | CFD | P00746 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.51 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137386 | 0.89 | BCL2 (0.66) | AOC3LIPGHDAC1EPHX2NR1H4 | |
| SCHEMBL5724620 | 0.89 | LIPG (0.60) | AOC3ERAP2ERAP1LNPEPLIPG | |
| SCHEMBL3145591 | 0.87 | AOC3 (0.52) | AOC3ERAP2ERAP1LNPEPLIPG | |
| SCHEMBL25542634 | 0.87 | LIPG (0.56) | AOC3ERAP2ERAP1LNPEPLIPG | |
| SCHEMBL1899410 | 0.85 | NPSR1 (0.57) | HDAC1KIF11KMT2AALDH1A1LMNA | |
| SCHEMBL23442907 | 0.85 | LIPG (0.54) | AOC3ERAP2ERAP1LNPEPLIPG | |
| SCHEMBL5801663 | 0.84 | KMT2A (0.65) | HDAC1EPHX2NR1H4KMT2AALDH1A1 | |
| SCHEMBL30259900 | 0.83 | AOC3 (0.72) | AOC3ERAP2ERAP1LNPEPLIPG | |
| SCHEMBL6230841 | 0.83 | AOC3 (0.63) | AOC3ERAP2ERAP1LNPEPLIPG | |
| SCHEMBL14365887 | 0.83 | AOC3 (0.63) | AOC3ERAP2ERAP1LNPEPLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1239472-C | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2006-02-01 | — | — | CN | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| CN-1441775-A | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | AOC3 66/4885ERAP2 3354/4885ERAP1 3119/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | AOC3 124/4885ERAP2 4006/4885ERAP1 3126/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | AOC3 124/4885ERAP2 4006/4885ERAP1 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.